BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 29368595)

  • 1. Short-term effects and safety of an acute increase of intraocular pressure after intravitreal bevacizumab injection on corneal endothelial cells.
    Park J; Lee M
    BMC Ophthalmol; 2018 Jan; 18(1):17. PubMed ID: 29368595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained intraocular pressure elevation in eyes treated with intravitreal injections of anti-vascular endothelial growth factor for diabetic macular edema in a real-life setting.
    Vo Kim S; Fajnkuchen F; Sarda V; Qu-Knafo L; Bodaghi B; Giocanti-Aurégan A
    Graefes Arch Clin Exp Ophthalmol; 2017 Nov; 255(11):2165-2171. PubMed ID: 28831613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness.
    Omay E; Elgin U; Sen E; Yilmazbas P
    Int Ophthalmol; 2016 Oct; 36(5):665-70. PubMed ID: 26780098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
    Choi DY; Ortube MC; McCannel CA; Sarraf D; Hubschman JP; McCannel TA; Gorin MB
    Retina; 2011 Jun; 31(6):1028-35. PubMed ID: 21836409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring intraocular pressure changes after intravitreal Ranibizumab injection using rebound tonometry.
    Fuest M; Kotliar K; Walter P; Plange N
    Ophthalmic Physiol Opt; 2014 Jul; 34(4):438-44. PubMed ID: 24731161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of intravitreal injection of bevacizumab with or without anterior chamber paracentesis on intraocular pressure and peripapillary retinal nerve fiber layer thickness: a prospective study.
    Soheilian M; Karimi S; Montahae T; Nikkhah H; Mosavi SA
    Graefes Arch Clin Exp Ophthalmol; 2017 Sep; 255(9):1705-1712. PubMed ID: 28616715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
    Hoang QV; Tsuang AJ; Gelman R; Mendonca LS; Della Torre KE; Jung JJ; Freund KB
    Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term intraocular pressure changes after intravitreal injection of bevacizumab.
    Baek SU; Park IW; Suh W
    Cutan Ocul Toxicol; 2016 Dec; 35(4):310-4. PubMed ID: 26820610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypotensive efficacy of topical brimonidine for intraocular pressure spikes following intravitreal injections of antivascular endothelial growth factor agents: a randomised crossover trial.
    Felfeli T; Hostovsky A; Trussart R; Yan P; Brent MH; Mandelcorn ED
    Br J Ophthalmol; 2019 Oct; 103(10):1388-1394. PubMed ID: 30573499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab.
    Segal O; Ferencz JR; Cohen P; Nemet AY; Nesher R
    Isr Med Assoc J; 2013 Jul; 15(7):352-5. PubMed ID: 23943979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
    Frenkel MP; Haji SA; Frenkel RE
    Arch Ophthalmol; 2010 Dec; 128(12):1523-7. PubMed ID: 21149773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect and safety of intravitreal injection of ranibizumab and bevacizumab on the corneal endothelium in the treatment of diabetic macular edema.
    Guzel H; Bakbak B; Koylu MT; Gonul S; Ozturk B; Gedik S
    Cutan Ocul Toxicol; 2017 Mar; 36(1):5-8. PubMed ID: 26911396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraocular Pressure Changes in Non-Glaucomatous Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Agents.
    Kiddee W; Montriwet M
    PLoS One; 2015; 10(9):e0137833. PubMed ID: 26360382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term changes of intraocular pressure and ocular perfusion pressure after intravitreal injection of bevacizumab or ranibizumab.
    Lee JW; Park H; Choi JH; Lee HJ; Moon SW; Kang JH; Kim YG
    BMC Ophthalmol; 2016 May; 16():69. PubMed ID: 27245159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term intraocular pressure changes after intravitreal injection of bevacizumab.
    Hollands H; Wong J; Bruen R; Campbell RJ; Sharma S; Gale J
    Can J Ophthalmol; 2007 Dec; 42(6):807-11. PubMed ID: 18026202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraocular Pressure in Eyes Receiving Intravitreal Antivascular Endothelial Growth Factor Injections.
    Lemos V; Cabugueira A; Noronha M; Abegão Pinto L; Reina M; Branco J; Gomes T
    Ophthalmologica; 2015; 233(3-4):162-8. PubMed ID: 25791262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration.
    Mathalone N; Arodi-Golan A; Sar S; Wolfson Y; Shalem M; Lavi I; Geyer O
    Graefes Arch Clin Exp Ophthalmol; 2012 Oct; 250(10):1435-40. PubMed ID: 22434210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term dynamic changes and influencing factors of corneal morphology after multiple intravitreal injections of anti-VEGF drugs.
    Qi Y; Li C; Ye S; Zhang Z; Li S; Zhang L
    Medicine (Baltimore); 2024 Apr; 103(17):e37937. PubMed ID: 38669379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections.
    Hoang QV; Mendonca LS; Della Torre KE; Jung JJ; Tsuang AJ; Freund KB
    Ophthalmology; 2012 Feb; 119(2):321-6. PubMed ID: 22054994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EFFECT OF SERIAL ANTERIOR CHAMBER PARACENTESIS ON SUSTAINED INTRAOCULAR PRESSURE ELEVATION IN PATIENTS RECEIVING INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Sisk RA; Rusia D; Zamora BG; Kuley A; Toussaint BW
    Retina; 2019 Oct; 39(10):1959-1964. PubMed ID: 30234855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.